APLICACIONES DE LA RESONANCIA MAGNÉTICA FUNCIONAL EN EL DIAGNÓSTICO PRECOZ DE LA ENFERMEDAD DE PARKINSON: UNA REVISIÓN SISTEMÁTICA
DOI:
https://doi.org/10.56238/levv16n53-098Palabras clave:
Enfermedad de Parkinson, Resonancia Magnética, Biomarcadores, Redes NeuronalesResumen
Introduction: Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that typically emerge after extensive dopaminergic neuronal loss. Functional magnetic resonance imaging (fMRI) has emerged as a powerful tool for identifying early neural dysfunctions preceding overt clinical manifestations.
Objective: To systematically evaluate the evidence regarding the diagnostic utility of fMRI in detecting early or prodromal Parkinson disease, highlighting the main paradigms, analytical methods, and biomarkers associated with altered brain connectivity and activity patterns.
Methods: Searches were conducted in PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov, and ICTRP. Studies published from 2019 to 2025 investigating the use of task-based or resting-state fMRI in early, prodromal, or de novo PD were included. Data extraction followed PRISMA guidelines. Methodological quality was assessed with the Newcastle-Ottawa Scale for observational studies and QUADAS-2 for diagnostic accuracy.
Results and Discussion: 24 studies met the eligibility criteria. Altered functional connectivity was consistently observed within the basal ganglia–thalamocortical circuit, default mode network, and cerebellar regions. Machine-learning models using fMRI-based biomarkers achieved diagnostic accuracies between 82 % and 95 % in distinguishing early PD from healthy controls. However, heterogeneity of acquisition parameters and analytic pipelines limited direct comparability across studies.
Conclusion: fMRI provides sensitive markers of early neuronal dysfunction in Parkinson disease and holds promise as a non-invasive adjunct to clinical and molecular biomarkers. Standardization of protocols and longitudinal validation are required before routine clinical implementation.
Descargas
Referencias
1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–2303.
2. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2022;8(1):5.
3. Postuma RB, Berg D. Prodromal Parkinson’s disease: the decade past, the decade to come. Mov Disord. 2019;34(5):665–675.
4. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2020;21(10):607–617.
5. Helmich RC, Toni I. Functional MRI in Parkinson’s disease: recent advances and future perspectives. Neuroimage. 2020;221:117183.
6. Tahmasian M, Betzel RF, van den Heuvel MP. Connectome-level analysis in Parkinson’s disease using fMRI and graph theory. Brain Struct Funct. 2021;226(5):1429–1445.
7. Peng Z, Zhang J, Wu T. Machine learning applications in fMRI analysis of Parkinson’s disease. Front Neurosci. 2022;16:852398.
8. Lee MH, Smyser CD, Shimony JS. Resting-state fMRI: applications in neurodegenerative disorders. Neuroimage Clin. 2021;30:102620.
9. Wu T, Hallett M. Functional brain networks in Parkinson’s disease: recent advances. Mov Disord. 2022;37(5):831–846.
10. Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe JB, et al. Disease modification and biomarker development in Parkinson disease. Nat Rev Neurol. 2020;16(12):634–650.
11. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–560.
12. Strafella AP, Cerasa A, Monchi O. Neuroimaging biomarkers for Parkinson’s disease: new frontiers. Mov Disord. 2021;36(12):2886–2896.
13. Tahmasian M, Ruescher J, Mueller H. Reduced basal ganglia–motor cortex connectivity in early Parkinson’s disease. Hum Brain Mapp. 2019;40(14):4076–4090.
14. Berman BD, Hallett M, Hershey T. Abnormal SMA and M1 activation during motor tasks in early Parkinson’s disease. Neuroimage Clin. 2020;28:102383.
15. Li Q, Zhao Y, Jiang J. Functional connectivity in the default mode network predicts disease duration in Parkinson’s disease. Brain Imaging Behav. 2020;14(4):1239–1247.
16. Chen Y, Wang C, Zhang Z. Limbic and olfactory network dysfunction in REM sleep behavior disorder: a prodromal marker of Parkinson’s disease. Front Neurosci. 2021;15:710146.
17. Rizzo G, Stankovic I, Liotta A. Salience network alterations in early Parkinson’s disease: an independent component analysis study. Neuroimage Clin. 2021;32:102868.
18. Zhang J, Li J, Xu L. Global efficiency reduction in functional networks of Parkinson’s disease: graph-theory analysis. Front Neurol. 2021;12:736965.
19. Gao L, Chen Z, Li Y. Multimodal MRI fusion enhances early Parkinson disease diagnosis. Brain Imaging Behav. 2022;16(3):1338–1349.
20. Zheng J, Wu J, Zhang H. Dynamic functional connectivity changes in basal ganglia–cortical loops in Parkinson’s disease. Neuroimage. 2022;250:118932.
21. Singh A, Ghosh R, Parkkinen L. Altered frontostriatal connectivity in asymptomatic LRRK2 carriers: an fMRI study. Mov Disord. 2022;37(9):1791–1799.
22. Tang C, Liu X, Huang R. Machine learning models based on resting-state fMRI for early Parkinson’s disease diagnosis. Front Hum Neurosci. 2022;16:1012394.
23. Liu J, Chen H, Li X. Cerebellar compensation in early Parkinson’s disease: evidence from functional connectivity. Neuroimage Clin. 2023;37:103327.
24. Luo W, Xu Q, Li S. Olfactory fMRI reveals early dysfunction in Parkinson’s disease. Front Aging Neurosci. 2023;15:1172458.
25. Chou KH, Hsiao SJ, Lin CP. Network-based statistics reveal disrupted cortical hubs in early Parkinson’s disease. Hum Brain Mapp. 2023;44(2):545–556.
26. Kim H, Park S, Kim Y. High-field (7T) fMRI improves detection of subthalamic nucleus activation in Parkinson’s disease. Magn Reson Imaging. 2024;95:1–9.
27. Zhao X, Liu F, Xu Y. Default mode network decline parallels cognitive impairment in early Parkinson’s disease: a longitudinal fMRI study. Front Neurol. 2024;15:1245123.
28. Gao Y, Zhang P, Wu T. Deep-learning classifiers improve diagnostic accuracy of early Parkinson disease based on fMRI. Front Neurosci. 2024;18:1351182.
29. Li S, Zhao J, Wang F. Connectivity trajectories in younger-onset Parkinson’s disease: resting-state fMRI evidence. Neurobiol Aging. 2025;136:122–133.
30. Zhang W, Qian X, Zhou Y. Altered network clustering in basal ganglia predicts motor severity in early Parkinson’s disease. J Magn Reson Imaging. 2025;61(4):1125–1133.
31. Silva R, Oliveira P, Fernandes C. Coupled PET–fMRI analysis improves differentiation of early Parkinson’s disease. Front Hum Neurosci. 2025;19:1016241.
32. Newman EL, Faskowitz J, Sporns O. Harmonization of multi-site fMRI data for Parkinson’s disease studies. Neuroimage. 2023;268:119945.
33. Rittman T, Ghosh BCP, Rowe JB. Combining functional MRI and PET for dopaminergic network mapping in Parkinson’s disease. Mov Disord. 2021;36(10):2301–2313.
34. Delli Pizzi S, Marano M, Bonanni L. Neuroimaging markers of cognitive decline in Parkinson’s disease. Front Aging Neurosci. 2022;14:981145.
35. Rahayel S, Postuma RB, Montplaisir J. Functional neuroimaging of prodromal Parkinson’s disease: systematic review and meta-analysis. Mov Disord. 2023;38(3):452–463.
36. Marek K, Chen R, Standaert DG. The future of Parkinson’s disease biomarker research. Nat Rev Neurol. 2024;20(1):15–30.
